Browse by category

Eli Lilly and Company has announced an agreement with the US government to expand access to its obesity medicines and reduce patient costs. In 2020, Lilly partnered with the Trump Administration on a pilot programme that paved the way for Lilly to be the first company to cap out-of-pocket insulin costs at $35 per month. Lilly will now improve access to nearly 40 million Americans living with obesity on government insurance programmes and millions more who pay out-of-pocket. U

The Obesity Society (TOS) has acknowledged the FDA’s recent announcement declaring the end of shortages for Novo Nordisk's Wegovy and...

The FDA has approved Eli Lilly and Company’s Zepbound (tirzepatide) as the first and only prescription medicine for adults with...

Eli Lilly and Company has announced Zepbound (tirzepatide) 2.5mg and 5mg single-dose vials are available for self-pay for patients with...

Detailed results from SURMOUNT-4 have shown Zepbound (tirzepatide) injection achieved superior mean percent change in body weight...

Eli Lilly and Company has announced that Zepbound (tirzepatide) injection is now available in US pharmacies for adults with obesity (with...

The FDA has approved Eli Lilly and Company's Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that...